BCM
IPSC icon

Bluefin Capital Management’s Century Therapeutics IPSC Stock Holding History

Bluefin Capital Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,018
Closed -$12K – 203
2025
Q3 		$12K Buy
+24,018
New +$12.9K ﹤0.01% 75

Other funds holding IPSC

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bluefin Capital Management's IPSC Position: Q4 2025 in Review

Bluefin Capital Management sold out of Century Therapeutics (IPSC) in Q4 2025, closing a stake of 24,018 shares — an estimated $12K sold.

Bluefin Capital Management first reported a position in IPSC in Q3 2025 and held it in 1 quarter. The position peaked at $12K in Q3 2025. 47 funds tracked by Wall St. Rank hold IPSC as of Q4 2025.

  • Bluefin Capital Management reported no remaining Century Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bluefin Capital Management sold 24,018 Century Therapeutics shares in Q4 2025, an estimated $12K.
  • Bluefin Capital Management first reported a position in Century Therapeutics in Q3 2025 and held it in 1 quarter.
  • Bluefin Capital Management's Century Therapeutics position peaked at $12K in Q3 2025.
  • 47 funds tracked by Wall St. Rank held Century Therapeutics as of Q4 2025.

Based on Bluefin Capital Management's 13F filing for Q4 2025, filed 29 Apr 2026.